Juniper Biosciences creates radiopharmaceuticals that combine radioisotopes with high‑affinity ligands to enable precise PET imaging and targeted radiotherapy of tumors. Their GMP‑compliant platform produces dual‑purpose agents that improve disease detection and deliver radiation directly to cancer cells while sparing healthy tissue.
Funding
Funding not disclosed
Founders
Product
Problem
Current diagnostic imaging and targeted cancer therapies often rely on non-specific agents that can produce ambiguous results, expose healthy tissue to radiation, and limit early detection of disease. This hampers clinicians’ ability to accurately stage tumors and deliver precise treatments, leading to suboptimal patient outcomes.
Solution
Juniper Biosciences develops radiopharmaceutical agents that couple radioisotopes with high‑specificity ligands to create both diagnostic and therapeutic solutions (theranostics). By selecting ligands that bind selectively to disease‑associated biomarkers, the agents enable clearer imaging of tumors and deliver radiation directly to malignant cells while sparing surrounding healthy tissue. All products are manufactured under stringent quality controls to ensure safety, reproducibility, and regulatory compliance. The platform supports a pipeline spanning multiple oncology indications, allowing earlier disease detection and more precise, personalized treatment regimens.
Target Audience
Primary customers are pharmaceutical and biotech companies developing oncology therapeutics, as well as academic and clinical research institutions conducting molecular imaging and targeted radiotherapy studies.
Features
- Radioisotope‑ligand conjugates engineered for high affinity to tumor‑specific molecular targets
- Dual‑purpose design enabling both positron emission tomography (PET) imaging and targeted radiotherapy
- GMP‑compliant manufacturing process that meets FDA and international quality standards
- Scalable synthesis platform adaptable to a variety of radioisotopes (e.g., ^68Ga, ^177Lu) for different clinical applications
- Integrated preclinical validation workflow including biodistribution, dosimetry, and safety profiling